STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #488 by analyst upside · 2026-06-27
IMUX
Immunic, Inc.
Healthcare · Market Cap $208M · P/E 0x
ANALYST PRICE TARGET
+191.9%
implied upside to consensus target
Current Price $15.3
Consensus Target $44.67
Bull Target $85.0
Bear Target $19.0
Analysts Covering 9
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
9
Hold
0
Sell
0
52-Week Low $5.06
52-Week High $15.77
YTD Return +162.4%
FUNDAMENTALS
Market Cap $208M
P/E Ratio (TTM) N/A
Forward P/E -4.3x
EPS (TTM) $-4.79
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $5.06
52-Week High $15.77
Current Price $15.3
Bear Target $19.0
Bull Target $85.0
● Now $15.3 ● Target $44.67
TRADING DATA
Avg Volume 271K
YTD Return +162.4%
Analyst Count 9
Consensus Buy
Upside to Target +191.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Immunic, Inc. (IMUX) is currently trading at $15.3 with a Wall Street consensus price target of $44.67, implying potential upside of 191.9% over the next 12 months. 9 analysts currently cover IMUX, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $85.0, while the most cautious has a target of $19.0.

IMUX operates in the Healthcare sector with a market capitalisation of $208M. The stock is up 162.4% year-to-date and is currently trading near the upper end of its 52-week range of $5.06 – $15.77.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IMUX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B. Riley Securities — Reiterated
Buy → Buy 2026-05-22 17% win rate (6 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-04-30 31% win rate (48 calls)
Stifel ● Initiated
Buy 2026-04-17 Building track record
D. Boral Capital ↓ Downgrade
Buy → Hold 2026-04-15 32% win rate (25 calls)
Guggenheim ● Initiated
Buy 2026-03-24 62% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-02 31% win rate (48 calls)
D. Boral Capital — Reiterated
Buy → Buy 2026-02-13 32% win rate (25 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-02-09 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →